Garadacimab Effective for Long-Term Prophylaxis of Hereditary angioedema: Study

A new study published in the recent issue of the Journal of the German Society of Dermatology found that garadacimab a subcutaneous monoclonal antibody targeting FXIIa in the kallikrein–kinin pathway, is approved for long-term prevention of attacks in Hereditary angioedema (HAE).

According to a new review it demonstrates rapid onset, sustained efficacy, and a favorable long-term safety profile, helping patients achieve better disease control and improved quality of life.

HAE attacks can affect various parts of the body, including the extremities, abdomen, and airways, with potentially life-threatening consequences. Current treatment guidelines highlight not just reducing attack frequency, but achieving complete prevention and restoring quality of life. However, this remains elusive for a substantial portion of patients using available therapies.

At the center of recent scientific progress is a deeper understanding of the biological pathway driving HAE. The condition is linked to dysregulation in the kallikrein–kinin system, which leads to excessive production of bradykinin, a peptide which is responsible for increased vascular permeability and swelling. A key upstream trigger in this cascade is Factor XII (FXII), which, when activated, initiates a chain reaction culminating in bradykinin release.

Targeting this pathway, this study developed garadacimab to inhibit activated FXII (FXIIa). By blocking this early step, garadacimab focuses on preventing the downstream production of bradykinin.

In the pivotal Phase III VANGUARD study, garadacimab demonstrated strong and sustained efficacy. The patients who received a subcutaneous injection with an initial loading dose followed by once-monthly maintenance, experienced a rapid onset of protection against HAE attacks. The treatment showed durable benefits over time, with many participants achieving significant reductions in attack frequency.

Throughout the long-term observation, the safety profile of garadacimab has remained favorable. This combination of efficacy, convenience, and tolerability positions the therapy as a potentially transformative option for HAE therapy. Overall, these findings suggest that garadacimab may help patients reach the complete disease control and normalization of life.

Source:

Aygören-Pürsün, E., Treudler, R., Staubach, P., Saguer, I. M., Linhoff, T., & Magerl, M. (2026). Garadacimab for the long-term prophylaxis of hereditary angioedema. Journal Der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]. https://doi.org/10.1111/ddg.70276